Pneumonitis is inflammation of lung tissue, often noninfectious, that can result from medications, radiation, autoimmune disease, or inhaled irritants and may progress to respiratory symptoms and fibrosis.
FDA approves AstraZeneca and Daiichi Sankyo's Datroway for first-line TNBC patients not eligible for PD-1/L1 inhibitors, based on Phase III TROPION-Breast02 data showing a 21% reduction in risk of death versus chemotherapy.
Incyte has started the phase 3 Dawn-03 trial of INCB161734 plus chemotherapy in first-line KRAS G12D-mutant pancreatic cancer. The move comes while the phase 1 study remains halted in four European countries after pneumonitis cases, including one grade 5 event.
Phase III KEYNOTE-B15 trial demonstrates enfortumab vedotin plus pembrolizumab significantly improves event-free survival and pathologic complete response rates compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.
Eli Lilly's Retevmo demonstrated statistically significant improvement in event-free survival versus placebo in stage II-IIIA RET fusion-positive non-small cell lung cancer following curative therapy in the phase 3 LIBRETTO-432 trial.
The FDA approved pembrolizumab (Keytruda) and Keytruda Qlex plus paclitaxel, with or without bevacizumab, for adults with PD-L1+ platinum-resistant ovarian carcinoma based on Phase 3 trial data showing improved survival outcomes.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06860542 |
Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis |
RECRUITING | PHASE2 |
| NCT06688422 |
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therapy |
RECRUITING | NA |
| NCT06670872 |
A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia |
NOT_YET_RECRUITING | |
| NCT05455034 |
Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis |
RECRUITING | PHASE1/PHASE2 |
| NCT05280873 |
Pirfenidone Combined With Methylprednisolone Versus Methylprednisolone in the Treatment of CIP |
UNKNOWN | PHASE1 |
| NCT04721444 |
Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19) |
COMPLETED | |
| NCT04590547 |
GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) |
COMPLETED | PHASE2 |
| NCT04370834 |
Tocilizumab for Patients With Cancer and COVID-19 Disease |
TERMINATED | PHASE2 |
| NCT04326725 |
Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia |
UNKNOWN | |
| NCT04302688 |
Accurate Classification System for Patients With COVID-19 Pneumonitis |
COMPLETED |
